Blank Check Company Ault Disruptive Technologies Corp Files For IPO Of Up To $100M; Co. Has Applied To List Units For Trading On NYSE American Under Symbol “ADRTU”

– Reuters

byBenzinga Newsdesk

November 5, 2021

1 minute read

– Reuters

Moderna Receives FDA Authorization For Emergency Use Of Omicron-Targeting Bivalent COVID-19 Booster Vaccine For Children And Adolescents 6 To 17 Years Of Age

By Benzinga Newsdesk

Today, 3:38 PM

mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccine Candidates CAMBRIDGE, MA / ACCESSWIRE / October 12, 2022

MRNA

Barclays Maintains Overweight on Cisco Systems, Raises Price Target to $62

By Benzinga Newsdesk

Today, 3:38 PM

Barclays analyst Tim Long maintains Cisco Systems (NASDAQ:CSCO) with a Overweight and raises the price target from $55 to $62.

CSCO

B of A Securities Upgrades Northern Oil & Gas to Buy, Announces $28 Price Target

By Benzinga Newsdesk

Today, 3:38 PM

B of A Securities analyst John Abbott upgrades Northern Oil & Gas (AMEX:NOG) from Neutral to Buy and announces $28 price target.

NOG

Shattuck Labs Announces Preliminary Clinical Data From Ongoing Phase 1 Clinical Trials Of ARC Fusion Proteins SL-172154 And SL-279252

By Benzinga Newsdesk

Today, 3:38 PM

– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients – – SL-172154 (SIRPα-Fc-CD40L)

STTK

Blank Check Company Ault Disruptive Technologies Corp Files For IPO Of Up To $100M; Co. Has Applied To List Units For Trading On NYSE American Under Symbol “ADRTU”

Related Posts

Moderna Receives FDA Authorization For Emergency Use Of Omicron-Targeting Bivalent COVID-19 Booster Vaccine For Children And Adolescents 6 To 17 Years Of Age

Barclays Maintains Overweight on Cisco Systems, Raises Price Target to $62

B of A Securities Upgrades Northern Oil & Gas to Buy, Announces $28 Price Target

Shattuck Labs Announces Preliminary Clinical Data From Ongoing Phase 1 Clinical Trials Of ARC Fusion Proteins SL-172154 And SL-279252